Elsevier Inc.

SHERPA: Unknown

People

  1. Abu-Rustum
    Abu-Rustum
  2. Chi
    Chi
  3. Lee
    Lee
  4. Giralt
    Giralt
  5. Mulhall
    Mulhall
  6. Perales
    Perales
  7. Sonoda
    Sonoda
  8. Leitao
    Leitao
  9. Yorke
    Yorke
  10. Wu
    Wu

Groups

  1. Department of Medicine (4608)
  2. Surgery (3547)
  3. Survivorship Research (2657)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2123)
  6. GSK Faculty (1936)
  7. Center for Hematologic Malignancies (1671)
  8. Hematologic Malignancies, Division of (1608)
  9. Gynecology Disease Management Team (1426)
  10. Sloan Kettering Institute Faculty (1398)
Search Within
Formats
  1. Journal Article (7381)
  2. Meeting Abstract (4692)
  3. Review (615)
  4. Book Section (538)
  5. Editorial (251)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4608)
  2. Surgery (3547)
  3. Survivorship Research (2657)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2123)
  6. GSK Faculty (1936)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (377)

More People

Years
  1. 2025 (244)
  2. 2024 (783)
  3. 2023 (760)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2611)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (967)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (525)
  6. Journal of Sexual Medicine (435)

More Publications

Results (13847)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The COBALT-LYM study of CTX130: A phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies
    Meeting Abstract

    Zain, D. R.; Iyer, S. P.; Sica, R. A.; Ho, P. J.; Hu, B.; Prica, A.; Weng, W. K.; Kim, Y. H.; Khodadoust, M. S.; Palomba, M. L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30
    Meeting Abstract

    Gerlach, M.; Schmitt, S.; Cyprys, P.; Kasper, M. A.; Mai, I.; Vermeer, M. H.; Horwitz, S. M.; Fingerle-Rowson, G.; Vogl, A.; Schumacher, D.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Cho, B. C.; Lin, J.; Camidge, D. R.; Velcheti, V.; Solomon, B.; Lu, S.; Lee, K. H.; Kim, S. W.; Kao, S.; Diadziuskzko, R.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Eng, J.; Yeh, R.; Girshman, J.; Das, J.; Gelblum, D.; Xu, A. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) (NCT01730937)
    Meeting Abstract

    Dawson, L. A.; Winter, K.; Knox, J.; Zhu, A. X.; Krishnan, S.; Guha, C.; Kachnic, L. A.; Gillin, M. T.; Hong, T. S.; Craig, T.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Prophylactic radiation therapy vs. standard-of-care for patients with high-risk, asymptomatic bone metastases: A multicenter, randomized phase II trial
    Meeting Abstract

    Gillespie, E. F.; Mathis, N. J.; Marine, C.; Zhang, Z.; Barker, C. A.; Guttmann, D. M.; Kotecha, R.; McIntosh, A. F.; Vaynrub, M.; Bartelstein, M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer (EXTEND): A multicenter, randomized phase II trial
    Meeting Abstract

    Tang, C.; Sherry, A. D.; Haymaker, C.; Bathala, T.; Liu, S.; Fellman, B.; Aparicio, A.; Zurita-Saavedra, A.; Chun, S.; Reddy, J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
    Journal Article

    Argilés, G.; Mulet, N.; Valladares-Ayerbes, M.; Viéitez, J. M.; Grávalos, C.; García-Alfonso, P.; Santos, C.; Tobeña, M.; García-Paredes, B.; Benavides, M.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Matching adjusted indirect comparison of PFS & OS comparing ribociclib + letrozole vs palbociclib + letrozole as first-line treatment of HR+/HER2− ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2
    Meeting Abstract

    Jhaveri, K.; O'Shaughnessy, J.; Fasching, P.; Cardoso, F.; Tolaney, S.; Hamilton, E.; Sharma, V. K.; Biswas, C.; Haftchenary, S.; Pathak, P.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • How prostate cancer patients are surveyed may influence self-reported sexual function responses
    Journal Article

    Papa, N.; Bensley, J. G.; Perera, M.; Evans, M.; Millar, J. L.
    Journal of Sexual Medicine (2022)

    Fulltext@MSK | Save